Literature DB >> 11124059

Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus.

T Todo1, F Feigenbaum, S D Rabkin, F Lakeman, J T Newsome, P A Johnson, E Mitchell, D Belliveau, J M Ostrove, R L Martuza.   

Abstract

G207 is a multimutated, conditionally replicating herpes simplex virus type 1 (HSV-1) that is currently in clinical trial for patients with malignant glioma. G207 exhibits an efficient oncolytic activity in tumor cells, yet minimal toxicity in normal tissue when injected into the brains of HSV-susceptible mice or nonhuman primates. In this study, we evaluated the shedding and biodistribution of clinical-grade G207 after intracerebral inoculation (3 x 10(7) pfu) in four New World owl monkeys (Aotus nancymae). Using PCR analyses and viral cultures, neither infectious virus nor viral DNA was detected from tear, saliva, or vaginal secretion samples at any time point up to 1 month postinoculation. Analyses of tissues obtained at necropsy at 1 month from two of the four monkeys, plus one monkey inoculated with laboratory-grade G207 (10(9) pfu) 2 years earlier, showed the distribution of G207 DNA restricted to the brain, although infectious virus was not isolated. Histopathology revealed normal brain tissues including the sites of inoculation. A measurable increase of serum anti-HSV antibody titer was observed in all monkeys, as early as 21 days postinoculation. The results ascertain the safety of G207 in the brain and indicate that strict biohazard management may not be required for G207-treated patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11124059     DOI: 10.1006/mthe.2000.0200

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  19 in total

1.  Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.

Authors:  T Todo; R L Martuza; S D Rabkin; P A Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

2.  HSV Recombinant Vectors for Gene Therapy.

Authors:  Roberto Manservigi; Rafaela Argnani; Peggy Marconi
Journal:  Open Virol J       Date:  2010-06-18

3.  Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12.

Authors:  James M Markert; James J Cody; Jacqueline N Parker; Jennifer M Coleman; Kathleen H Price; Earl R Kern; Debra C Quenelle; Alfred D Lakeman; Trenton R Schoeb; Cheryl A Palmer; Samuel C Cartner; G Yancey Gillespie; Richard J Whitley
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

4.  Real-time intraoperative detection of breast cancer axillary lymph node metastases using a green fluorescent protein-expressing herpes virus.

Authors:  David P Eisenberg; Prasad S Adusumilli; Karen J Hendershott; Sun Chung; Zhenkun Yu; Mei-Ki Chan; Michael Hezel; Richard J Wong; Yuman Fong
Journal:  Ann Surg       Date:  2006-06       Impact factor: 12.969

Review 5.  Oncolytic virus therapy using genetically engineered herpes simplex viruses.

Authors:  Tomoki Todo
Journal:  Hum Cell       Date:  2002-09       Impact factor: 4.174

6.  5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer.

Authors:  David P Eisenberg; Prasad S Adusumilli; Karen J Hendershott; Zhenkun Yu; Michael Mullerad; Mei-Ki Chan; Ting-Chao Chou; Yuman Fong
Journal:  J Gastrointest Surg       Date:  2005-11       Impact factor: 3.452

Review 7.  Advances in oncolytic virus therapy for glioma.

Authors:  Amy Haseley; Christopher Alvarez-Breckenridge; Abhik Ray Chaudhury; Balveen Kaur
Journal:  Recent Pat CNS Drug Discov       Date:  2009-01

8.  A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses.

Authors:  James M Markert; Shantanu N Razdan; Hui-Chien Kuo; Alan Cantor; Anette Knoll; Matthias Karrasch; L Burt Nabors; Michael Markiewicz; Bonita S Agee; Jennifer M Coleman; Alfred D Lakeman; Cheryl A Palmer; Jacqueline N Parker; Richard J Whitley; Ralph R Weichselbaum; John B Fiveash; G Yancey Gillespie
Journal:  Mol Ther       Date:  2014-02-27       Impact factor: 11.454

9.  Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1.

Authors:  Jayson Hardcastle; Kazuhiko Kurozumi; Nina Dmitrieva; Martin P Sayers; Sarwat Ahmad; Peter Waterman; Ralph Weissleder; E Antonio Chiocca; Balveen Kaur
Journal:  Mol Ther       Date:  2009-10-20       Impact factor: 11.454

10.  Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses.

Authors:  Prasad S Adusumilli; Brendon M Stiles; Mei-Ki Chan; Michael Mullerad; David P Eisenberg; Leah Ben-Porat; Rumana Huq; Valerie W Rusch; Yuman Fong
Journal:  J Gene Med       Date:  2006-05       Impact factor: 4.565

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.